Biomarker defined acute optic neuritis
10.5124/jkma.2024.67.8.517
- Author:
Haeng-Jin LEE
1
Author Information
1. Department of Ophthalmology, Jeonbuk National University College of Medicine, Jeonju, Korea
- Publication Type:Focused Issue of This Month
- From:Journal of the Korean Medical Association
2024;67(8):517-523
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Optic neuritis, an inflammation of the optic nerve, commonly occurs in young adults and often associated with demyelinating diseases, such as multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody disease (MOGAD), and acute disseminated encephalomyelitis. These conditions frequently exhibit recurrent and progressive inflammatory episodes, significantly impacting prognosis. Differentiating these diseases is crucial because of their distinct clinical presentations, treatment responses, and outcomes. Recent advancements in biomarkers, such as aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein (MOG) antibodies, have enhanced diagnostic precision.Current Concepts: The introduction of AQP4 and MOG-immunoglobulin G (IgG) antibody testing has revolutionized diagnostic approaches for optic neuritis. AQP4-IgG is a highly specific marker for NMOSD, facilitating early diagnosis, essential for timely intervention and improved patient outcomes. MOG-IgG has been identified as a distinct marker for MOGAD, differentiating it from MS and NMOSD. These biomarkers aid in understanding the pathophysiological mechanisms underlying optic neuritis and in tailoring individualized treatment strategies.Discussion and Conclusion: The use of AQP4 and MOG-IgG antibodies represents a significant leap forward in managing optic neuritis. These biomarkers not only assist in accurate diagnosis but also provide insights into disease prognosis and therapeutic responses. Future studies should focus on the detailed clinical and pathological characteristics associated with these biomarkers to refine treatment protocols further and enhance patient care. Continued advancements in biomarker research hold promise for the development of new therapeutic avenues and the potential for improved long-term outcomes in patients with optic neuritis.
